Ovarian Cancer

Introduction; PART 1: AETIOLOGY; 1. Epidemiology of sporadic ovarian cancer; 2. Associations between infertility, its treatment and ovarian cancer risk; 3. The molecular basis of sporadic ovarian cancer; 4. Overview of the aetiology of familial ovarian cancer; 5. The prevalence of mutations in BRCA1 and BRCA2; 6. The penetrance of BRCA1/2 mutations; 7. Founder mutations of BRCA1/2; 8. Clinical implications of genetic testing; PART 2: NATURAL HISTORY AND PATHOLOGY; 9. Pathology of epithelial ovarian cancer; 10. Pathology of borderline ovarian malignancy; 11. Primary non-epithelial ovarian cancers; 12. Metastases in the ovary; 13. Genetic analysis of putative precursors of ovarian cancer; 14. Molecular pathogenesis of borderline and invasive ovarian tumours; PART 3: TUMOR BIOLOGY; 15. The application of novel technology to the study of ovarian cancer; 16. The biology of the ovarian surface epithelium; 17. The tumour microenvironment of epithelial ovarian cancer; 18. ARHI (NOEY2), a novel imprinted tumour suppressor gene in ovarian cancer; 19. Regulation of angiogenesis in ovarian cancer: role of p53, vascular endothelial growth factor, and hypoxia; 20. Role of Fas/FasL in the control of human ovary growth and progression; PART 4: PREVENTION AND SCREENING; 21. The surgical prevention of ovarian cancer; 22. Chemoprevention of ovarian cancer; 23. Biologic effect of progestins on ovarian epithelium: cancer prevention through apoptosis?; 24. The current status of screening for ovarian cancer; 25. Optimising the use of ultrasonography in ovarian cancer screening; 26. Doppler ultrasound derived indices in screening and diagnosis of ovarian cancer; 27. Differentiating the risk of ovarian cancer calculation from CA125 velocity: a new concept for optimizing CA125 screening for ovarian cancer; 28. Socioeconomics of ovarian cancer screening; 29. The management of familial ovarian cancer; PART 5: DIAGNOSTIC AND PROGNOSTIC TECHNIQUES; 30. Clinical diagnosis including para-neoplastic syndromes; 31. Serum tumour markers in the clinical management of ovarian cancer; 32. Three-dimensional ultrasound and color-flow studies; 33. CT and MRI of ovarian cancer; 34. Radionuclide imaging; 35. Telomerase in ovarian cancer: possible diagnostic test and therapeutic target; 36. Detection of circulating tumour cells in the peripheral blood and bone marrow of patients with ovarian cancer; PART 6: SURGICAL MANAGEMENT OF OVARIAN CANCER; 37. Overview of primary surgery for ovarian cancer; 38. Interval debulking surgery significantly increases the survival and progression-free survival in advanced epithelial ovarian cancer patients: an EORTC Gynaecological Cancer Co-operative Group study; 39. The role of surgery in relapse and palliation of ovarian cancer; 40. The role of minimal access surgery in ovarian cancer; 41. The organization of care; 42. Patterns of care in ovarian cancer; PART 7: ADJUVANT AND PALLIATIVE THERAPY FOR OVARIAN CANCER; 43. Current chemotherapy options in ovarian cancer; 44. Chemotherapy for epithelial cancer of the ovary; 45. Neoadjuvant chemotherapy in advanced ovarian carcinoma: present and future prospects; 46. Randomized trials in epithelial ovarian cancer: the Gynaecological Oncology Group studies; PART 8: NOVEL THERAPIES: THE FUTURE; 47. Angiogenesis in epithelial ovarian cancer: an important biological event and therapeutic target; 48. Delivery of genes to ovarian cancer using targeted vectors based on self-assembling polymers; 49. Corporate drug discovery strategies; 50. DNA mismatch repair and drug resistance; 51. Gene therapy and immunomodulation; 52. Preclinical and phase 1 clinical studies of combinations of chemotherapy with recombinant adenovirus containing full-length, human p53 tumor suppressor gene cDNA for p53-mutant ovarian cancer; 53. Paclitaxel resistance in human ovarian cancer: role of apoptosis-related proteins; 54. Trials of p53 gene therapy: rationale and preliminary studies; 55. Phosphatidylinostol 3'-kinase as a target in ovarian cancer: from genomics to therapeutics